Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened versus standard chemotherapy plus immunotherapy for first-line high-tumor-burden follicular lymphoma
2020-003277-22Phase 3Active
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, obinutuzumab, bendamustine, cyclophosphamide, doxorubicin and 2 more in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Started Oct 2021; status: active.
02
Drugs
rituximabobinutuzumabbendamustinecyclophosphamidedoxorubicin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2020-003277-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003277-22.